Legend Biotech Q1 CARVYKTI® Sales Jump 62% to $597M on Global Expansion
LEGN•Legend Biotech’s CARVYKTI® net sales rose 62% year-over-year to $597 million in Q1 2026, with US sales up 36% and ex-US sales up 222% after launches in four new markets, reaching 18 global markets. The company held $834.6 million in cash and narrowed net loss to $10.5 million, extending runway toward profitability beyond 2026.
1. Sales Growth and Global Expansion
Legend Biotech reported net trade sales for CARVYKTI grew 62% to $597 million in Q1 2026, with US sales increasing 36% and ex-US sales surging 222% following product launches in Italy, Poland, the Czech Republic and Australia, bringing availability to 18 markets across 300 sites.
2. Financial Performance and Cash Position
The company ended March 31, 2026, with $834.6 million in cash and time deposits, reinforced by $55 million of milestones from its Janssen agreement, and narrowed its net loss to $54.3 million, with non-GAAP net loss of $10.5 million, reflecting improving operating leverage.
3. Manufacturing and Pipeline Advances
Legend Biotech improved CARVYKTI manufacturing capabilities to a 99% success rate, reduced turnaround times, and achieved over 95% on-time delivery; it also advanced its early-stage cell therapy portfolio with multiple data presentations slated at medical conferences in 2026.
